Topics:
Genitourinary Cancers • Prostate Cancer • Medical Oncology • Journal Club ft. NEJM publications
What could explain the discordant results between PARP/abiraterone combinations in MAGNITUDE and PROpel in non-HRRm prostate cancer?
Is the benefit in PROpel driven by BRCA1/2 or ATM mutated tumors vs all comers?
Answer from: Medical Oncologist at Academic Institution
This is an important question. I would summarize this below:
1. Differences in study design and patient populations
MAGNITUDE allowed prior ARSI (5%), prior exposure to abiraterone for up to 4 mo which could have been selected for patients less sensitive to abiraterone where PARPi combination sy...
Sign in or Register to read more